ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 120 filers reported holding ARBUTUS BIOPHARMA CORP in Q1 2023. The put-call ratio across all filers is 0.29 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $412,952 | +66.3% | 136,288 | +27.9% | 0.00% | – |
| Q4 2022 | $248,253 | +589.6% | 106,546 | +464.7% | 0.00% | – |
| Q3 2022 | $36,000 | -68.7% | 18,869 | -55.7% | 0.00% | – |
| Q2 2022 | $115,000 | -91.1% | 42,601 | -90.2% | 0.00% | – |
| Q1 2022 | $1,296,000 | -60.6% | 434,714 | -48.6% | 0.00% | – |
| Q4 2021 | $3,293,000 | +66.6% | 846,380 | +83.7% | 0.00% | – |
| Q3 2021 | $1,977,000 | +924.4% | 460,861 | +624.2% | 0.00% | – |
| Q2 2021 | $193,000 | -63.8% | 63,635 | -60.3% | 0.00% | – |
| Q1 2021 | $533,000 | -45.1% | 160,362 | -41.4% | 0.00% | – |
| Q4 2020 | $971,000 | +1732.1% | 273,464 | +1525.3% | 0.00% | – |
| Q3 2020 | $53,000 | -72.7% | 16,825 | -84.2% | 0.00% | – |
| Q2 2020 | $194,000 | +165.8% | 106,181 | +45.6% | 0.00% | – |
| Q1 2020 | $73,000 | -79.0% | 72,925 | -56.4% | 0.00% | -100.0% |
| Q2 2019 | $348,000 | +411.8% | 167,188 | +1422.2% | 0.00% | – |
| Q3 2017 | $68,000 | -56.1% | 10,983 | -56.7% | 0.00% | -100.0% |
| Q3 2015 | $155,000 | – | 25,374 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Whitefort Capital Management, LP | 11,895,477 | $24,147,818 | 12.66% |
| Two Seas Capital LP | 8,280,818 | $16,810,061 | 3.38% |
| FourWorld Capital Management LLC | 1,341,907 | $2,724,071 | 0.51% |
| Tejara Capital Ltd | 180,077 | $365,556 | 0.21% |
| Woodline Partners LP | 4,719,903 | $9,581,403 | 0.11% |
| Hudson Bay Capital Management LP | 8,299,808 | $16,848,610 | 0.07% |
| Kepos Capital LP | 155,691 | $316 | 0.06% |
| Virtus ETF Advisers LLC | 40,040 | $81,281 | 0.05% |
| Centiva Capital, LP | 1,071,705 | $2,175,561 | 0.05% |
| Kades & Cheifetz LLC | 20,000 | $40,600 | 0.03% |